Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
07.03.2025 16:07:18
|
Eli Lilly's Ebglyss Monotherapy Injection Shows Sustained Skin Clearance In Atopic Dermatitis
(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three years.
Findings from the ADjoin long-term extension study will be presented at the American Academy of Dermatology Annual Meeting from March 7-11 in Orlando.
Among patients receiving a once-monthly maintenance dose, 50 percent achieved complete skin clearance, while 87 percent maintained almost-clear skin at three years. Most patients did not require additional topical treatments. Ebglyss, an interleukin-13 inhibitor, continues to show a consistent safety profile with no new safety concerns, the company said.
LLY is currently trading at $905.91 down 0.75 percent or $6.85 on the New York Stock Exchange.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 710,50 | 1,79% |
|